StudyFinder

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants with Biochemical Recurrence of Prostate Cancer

Status: Recruiting

The primary purpose of this study is to see how well the 64Cu-SAR-bisPSMA PET/CT scan can find prostate cancer that has come back, based on expert review.

I'm interested

Sex: Male
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• confirmed adenocarcinoma of prostate (PC)
• completed definitive therapy
• able to do all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
• see link to clinicaltrials.gov for complete Inclusion criteria
Exclusion Criteria:

• small cell or neuroendocrine PC
• ongoing treatment or treatment within 6 months with any systemic therapy (e.g. any investigational therapy, androgen-deprivation therapy, antiandrogen, gonadotropin-releasing hormone, luteinizing hormone-releasing hormone agonist or antagonist, chemotherapy, immunotherapy or radiotherapy) for PC
• see link to clinicaltrials.gov for complete Exclusion criteria
Interventions:

Drug: 64Cu-SAR-bisPSMA

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Prostate Cancer, Radiotherapy. PC

Study Contact: Emmanuel Antonarakis - anton401@umn.edu
Principal Investigator: Emmanuel Antonarakis
Phase: PHASE3
IRB Number: STUDY00026349
See this study on ClinicalTrials.gov

Back